Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
133 hedge funds and large institutions have $341M invested in Sciclone Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 52 reducing their positions, and 21 closing their positions.
6,600% more call options, than puts
Call options by funds: $67K | Put options by funds: $1K
1% less funds holding
Funds holding: 134 → 133 (-1)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
21% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 52
60% less capital invested
Capital invested by funds: $860M → $341M (-$519M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.36M |
| 2 |
Millennium Management
New York
|
+$3.34M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.16M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.01M |
| 5 |
Renaissance Technologies
New York
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Americafirst Capital Management
Roseville,
California
|
-$607M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.8M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$7.44M |
| 4 |
PP
PDT Partners
New York
|
-$2.17M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$2.13M |
SCLN Hedge Fund Activity: Q4 2015 in Review
133 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2015, worth a combined $341M — down 60% from $860M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SCLN and 20 opened new positions — a net loss of 1 holder — while 52 trimmed existing stakes and 41 added.
The largest buyer was Nantahala Capital Management, adding an estimated $3.36M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $607M sold.
- 133 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2015, down from 134 in Q3 2015.
- Funds reported $341M of Sciclone Pharmaceuticals Inc stock for Q4 2015, down 60% quarter-over-quarter.
- 20 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2015 and 21 closed out, a net change of -1 holder.
- The largest Sciclone Pharmaceuticals Inc buyer in Q4 2015 was Nantahala Capital Management, an estimated $3.36M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q4 2015 was Americafirst Capital Management, an estimated $607M sold.
Based on aggregated 13F filings for Q4 2015.